{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T01:10:57Z","timestamp":1768266657510,"version":"3.49.0"},"reference-count":105,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Gout, a metabolic and autoinflammatory disease, is the most common form of inflammatory arthritis worldwide. Hyperuricemia may result in monosodium urate (MSU) crystals forming and depositing in joints and surrounding tissues, triggering an autoinflammatory response. Effective urate-lowering therapies, as well as anti-inflammatory medications, are used to treat gout. Over the past few decades, new antihyperglycemic drug classes with different modes of action have been added to treat hyperglycemia in type 2 diabetes mellitus (T2DM). Two of these drug classes, sodium\u2013glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), have reduced cardiovascular and renal events and mortality. Several clinical studies have demonstrated that SGLT2 inhibitors possess urate-lowering properties, which may be beneficial for treating gout patients, particularly those with comorbid T2DM. Regarding SGLT2 inhibitors, some researchers have suggested that their benefits are partly explained by their ability to reduce serum urate (SU) levels, probably through increased urinary uric acid excretion. The effect of GLP-1 RA on SU levels and urinary excretion of uric acid in humans is unclear. This paper reviews the mechanisms of action of SGLT2 inhibitors and GLP-1RA, both approved and in development. Additionally, it examines what is known about their structure\u2013activity relationships, uricosuric effects, pharmacokinetic profiles, and adverse effects.<\/jats:p>","DOI":"10.3390\/pharmaceutics17070865","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T06:46:12Z","timestamp":1751438772000},"page":"865","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Could Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Play a Role in Gout Treatment?"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9836-1370","authenticated-orcid":false,"given":"Dan","family":"Kaufmann","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84132, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1558-1202","authenticated-orcid":false,"given":"Naomi","family":"Schlesinger","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84132, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e239501","DOI":"10.1001\/jamanetworkopen.2023.9501","article-title":"Trends in Prevalence of Gout Among US Asian Adults, 2011\u20132018","volume":"6","author":"Yokose","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Krishnan, E. (2012). Reduced glomerular function and prevalence of gout: NHANES 2009\u201310. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050046"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1751-7176.2012.00674.x","article-title":"Hypertension and the risk of incident gout in a population-based study: The atherosclerosis risk in communities cohort","volume":"14","author":"Maynard","year":"2012","journal-title":"J. Clin. Hypertens."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.clinthera.2024.04.013","article-title":"Newer Glucose-Lowering Drugs and Risk of Gout: A Network Meta-Analysis of Randomized Outcomes Trials","volume":"46","author":"Wang","year":"2024","journal-title":"Clin. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/13548506.2019.1707241","article-title":"Gout and risk of diabetes mellitus: Meta-analysis of observational studies","volume":"25","author":"Zhao","year":"2020","journal-title":"Psychol. Health Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.4155\/fmc-2020-0154","article-title":"SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: An extensive review","volume":"12","author":"Manoj","year":"2020","journal-title":"Future Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1152\/physrev.1994.74.4.993","article-title":"Molecular physiology of sodium-glucose cotransporters","volume":"74","author":"Hediger","year":"1994","journal-title":"Physiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Norton","year":"2011","journal-title":"Endocr. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: A review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_11","unstructured":"Chackalamannil, S., Rotella, D., and Ward, S.E. (2017). 7.13\u2014Sodium\u2013Glucose Cotransporters. Comprehensive Medicinal Chemistry III, Elsevier."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Muller","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Harmar, A.J. (2001). Family-B G-protein-coupled receptors. Genome Biol., 2.","DOI":"10.1186\/gb-2001-2-9-reports0028"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/bph.15485","article-title":"Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands","volume":"179","author":"Tanday","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting","volume":"48","author":"Korner","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 Receptor Expression Within the Human Heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e13073","DOI":"10.14814\/phy2.13073","article-title":"Glucagon-like peptide-1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men","volume":"5","author":"Asmar","year":"2017","journal-title":"Physiol. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1210\/jc.2019-00004","article-title":"Extracellular Fluid Volume Expansion Uncovers a Natriuretic Action of GLP-1: A Functional GLP-1-Renal Axis in Man","volume":"104","author":"Asmar","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): Effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejps.2016.08.025","article-title":"Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective","volume":"93","author":"Madaan","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_22","first-page":"656","article-title":"Canagliflozin (invokana), a novel oral agent for type-2 diabetes","volume":"38","author":"Hilas","year":"2013","journal-title":"Pharm. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.clinthera.2015.04.015","article-title":"Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects","volume":"37","author":"Chen","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2014.05.2753","article-title":"Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: Pooled analysis of phase 3 study results","volume":"126","author":"Usiskin","year":"2014","journal-title":"Postgrad. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dom.12439","article-title":"Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus","volume":"17","author":"Davies","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/dom.15191","article-title":"Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial","volume":"25","author":"Doi","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/S2665-9913(19)30078-5","article-title":"The effects of canagliflozin on gout in type 2 diabetes: A post-hoc analysis of the CANVAS Program","volume":"1","author":"Li","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/17446651.2025.2456504","article-title":"Hypouricemic effect of sodium glucose transporter-2 inhibitors: A network meta-analysis and meta-regression of randomized clinical trials","volume":"20","author":"Sridharan","year":"2025","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1111\/dom.15157","article-title":"Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: A meta-analysis and meta-regression of randomized controlled trials","volume":"25","author":"Banerjee","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","article-title":"Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/dom.14559","article-title":"Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial","volume":"24","author":"Ferreira","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/dom.13991","article-title":"Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: The EMPEROR-reduced trial","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"108436","DOI":"10.1016\/j.jdiacomp.2023.108436","article-title":"The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study","volume":"37","author":"Bechlioulis","year":"2023","journal-title":"J. Diabetes Complications."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.jchf.2024.08.020","article-title":"Uric Acid and SGLT2 Inhibition with Empagliflozin in Heart Failure with Preserved Ejection Fraction: The EMPEROR-Preserved Trial","volume":"12","author":"Doehner","year":"2024","journal-title":"JACC Heart Fail"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/ndt\/gfae203","article-title":"Empagliflozin lowers serum uric acid in chronic kidney disease: Exploratory analyses from the EMPA-KIDNEY trial","volume":"40","author":"Mayne","year":"2024","journal-title":"Nephrol. Dial Transpl."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7520632","DOI":"10.1155\/2022\/7520632","article-title":"Impacts of Sodium\/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis","volume":"2022","author":"Akbari","year":"2022","journal-title":"J. Diabetes Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/dom.14570","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis","volume":"24","author":"Hu","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ejhf.2433","article-title":"Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF","volume":"24","author":"McDowell","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamacardio.2022.5608","article-title":"Association of Dapagliflozin Use with Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients with Heart Failure with and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER","volume":"8","author":"Butt","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e2347","DOI":"10.1210\/clinem\/dgaa748","article-title":"Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study","volume":"106","author":"Stack","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/dom.14018","article-title":"A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes","volume":"22","author":"Mulder","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"174169","DOI":"10.1016\/j.ejphar.2021.174169","article-title":"The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics","volume":"904","author":"Kaur","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1185\/03007995.2014.901943","article-title":"Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A 12-week, randomized, placebo-controlled, phase II study","volume":"30","author":"Seino","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1185\/03007995.2014.912983","article-title":"Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, phase 3 study","volume":"30","author":"Seino","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clinthera.2015.10.025","article-title":"Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus","volume":"38","author":"Haneda","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.clinthera.2016.01.017","article-title":"Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data from 52-Week Phase III Trials","volume":"38","author":"Sakai","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/jdi.12156","article-title":"Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus","volume":"5","author":"Kashiwagi","year":"2014","journal-title":"J. Diabetes Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"586","DOI":"10.14740\/jocmr3038w","article-title":"Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients with Type 2 Diabetes Mellitus","volume":"9","author":"Kawata","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2169\/internalmedicine.3473-19","article-title":"Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial","volume":"59","author":"Tanaka","year":"2020","journal-title":"Intern. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/dom.12957","article-title":"Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP\/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial","volume":"19","author":"Terauchi","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1475-2840-13-65","article-title":"Efficacy and safety of monotherapy with the novel sodium\/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: A combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study","volume":"13","author":"Kaku","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2337\/cd18-0097","article-title":"Overview of Ertugliflozin","volume":"37","author":"Nguyen","year":"2019","journal-title":"Clin. Diabetes"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1111\/dom.15895","article-title":"Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV","volume":"26","author":"Sridhar","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1111\/bcp.15344","article-title":"The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis","volume":"88","author":"Najafi","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","article-title":"Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes","volume":"117","author":"Nielsen","year":"2004","journal-title":"Regul. Pept."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s001250050903","article-title":"Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity","volume":"41","author":"Deacon","year":"1998","journal-title":"Diabetologia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/dom.12601","article-title":"Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men","volume":"18","author":"Muskiet","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/dom.13223","article-title":"Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials","volume":"20","author":"Tonneijck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s00125-016-3938-z","article-title":"Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: A randomised, double-blind, placebo-controlled trial","volume":"59","author":"Tonneijck","year":"2016","journal-title":"Diabetologia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"F934","DOI":"10.1152\/ajprenal.00603.2018","article-title":"A model of uric acid transport in the rat proximal tubule","volume":"316","author":"Edwards","year":"2019","journal-title":"Am. J. Physiol.-Renal Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: A prospective randomized clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s40265-014-0320-7","article-title":"Dulaglutide: First global approval","volume":"74","author":"Sanford","year":"2014","journal-title":"Drugs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-015-0338-3","article-title":"Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials","volume":"55","author":"Geiser","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_70","first-page":"EP621","article-title":"Dulaglutide added on Empagliflozin improves blood pressure, body weight, glycemic control and albuminuria in obese diabetic patients","volume":"49","author":"Kuzior","year":"2017","journal-title":"Endocr. Abstr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s13340-018-0348-0","article-title":"Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: A single-center, open-label, single-arm, pilot study","volume":"9","author":"Iwasaki","year":"2018","journal-title":"Diabetol. Int."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: Randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"eadh4453","DOI":"10.1126\/scitranslmed.adh4453","article-title":"Seeking satiety: From signals to solutions","volume":"15","author":"Tschop","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s40200-021-00899-9","article-title":"Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists","volume":"20","author":"Okamoto","year":"2021","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_77","first-page":"9908","article-title":"Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults","volume":"27","author":"Xiang","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Reppo, I., Jakobson, M., and Volke, V. (2023). Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065714"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Knudsen, L.B., and Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00155"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e2415550121","DOI":"10.1073\/pnas.2415550121","article-title":"The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity","volume":"121","author":"Friedman","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/jdi.13314","article-title":"Evaluation of the efficacy of low-dose liraglutide in weight control among Taiwanese non-diabetes patients","volume":"11","author":"Chou","year":"2020","journal-title":"J. Diabetes Investig."},{"key":"ref_82","first-page":"A125","article-title":"Efficacy and Safety Evaluation of Liraglutide Treatment in Morbid Obese and Diabetic Patients in First Year of Commercialization in Spain","volume":"15","author":"Molero","year":"2013","journal-title":"Diabetes Technol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e13007","DOI":"10.1111\/eci.13007","article-title":"Liraglutide relieves cardiac dilated function than DPP-4 inhibitors","volume":"48","author":"Hiramatsu","year":"2018","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1479164120971220","DOI":"10.1177\/1479164120971220","article-title":"Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment","volume":"17","author":"Hiramatsu","year":"2020","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/jdi.13270","article-title":"Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study","volume":"11","author":"Nakaguchi","year":"2020","journal-title":"J. Diabetes Investig."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13098-016-0202-0","article-title":"Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: The PAGE1 study","volume":"9","author":"Ishii","year":"2017","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_87","first-page":"344","article-title":"Adropin-Potential Link in Cardiovascular Protection for Obese Male Type 2 Diabetes Mellitus Patients Treated with Liraglutide","volume":"59","author":"Milicevic","year":"2020","journal-title":"Acta Clin. Croat."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/dom.13541","article-title":"Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial","volume":"21","author":"Liakos","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/annrheumdis-2020-eular.3088","article-title":"OP0172 Effect of Weight Loss and Liraglutide on Serum Urate Levels among Obese Knee Osteoarthritis Patients: Secondary Analysis of a Randomised Controlled Trial","volume":"79","author":"Zobbe","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"101691","DOI":"10.1016\/j.eclinm.2022.101691","article-title":"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial","volume":"54","author":"Ji","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1856-LB","DOI":"10.2337\/db24-1856-LB","article-title":"1856-LB: Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1)","volume":"73","author":"JI","year":"2024","journal-title":"Diabetes"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"101088","DOI":"10.1016\/j.eclinm.2021.101088","article-title":"IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study","volume":"39","author":"Ji","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/pds.5252","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis","volume":"30","author":"Lund","year":"2021","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/M19-2610","article-title":"Assessing the Risk for Gout with Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes: A Population-Based Cohort Study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Alsalem, A., Alsultan, M.M., Alqarni, F., Almangour, A., Alsharekh, L., Alenazi, S., Alzahrani, S., Almanqour, R.A., Alazmi, A., and Alzahrani, A. (2024). Real-world evidence of the effects of sodium-glucose co-transporter 2 inhibitors on the dosing of diuretics in patients with heart failure: A retrospective cohort study. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1366439"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/17446651.2025.2480695","article-title":"Possible attenuation of gout risk by SGLT-2 inhibitors in patients using thiazide and loop diuretics","volume":"20","author":"Sridharan","year":"2025","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Sun, H.L., Wu, Y.W., Bian, H.G., Yang, H., Wang, H., Meng, X.M., and Jin, J. (2021). Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.667753"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Kimura, T., Takahashi, M., Yan, K., and Sakurai, H. (2014). Expression of SLC2A9 isoforms in the kidney and their localization in polarized epithelial cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0084996"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","article-title":"SGLT2 inhibition and renal urate excretion: Role of luminal glucose, GLUT9, and URAT1","volume":"316","author":"Novikov","year":"2019","journal-title":"Am. J. Physiol.-Renal Physiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/BOR.0000000000001030","article-title":"SGLT-2 inhibitors: New horizons for rheumatologists","volume":"36","author":"Chakrabarti","year":"2024","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Komiya, C., Tsuchiya, K., Shiba, K., Miyachi, Y., Furuke, S., Shimazu, N., Yamaguchi, S., Kanno, K., and Ogawa, Y. (2016). Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151511"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10557-019-06915-8","article-title":"Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues-Liraglutide and Semaglutide","volume":"33","author":"Basalay","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","article-title":"Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion","volume":"109","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2337\/db14-1577","article-title":"GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R","volume":"64","author":"Yusta","year":"2015","journal-title":"Diabetes"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/7\/865\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:59Z","timestamp":1760032919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/7\/865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":105,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["pharmaceutics17070865"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17070865","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}